Interesting academic highlights article discussing the FDAs pregnancy and lactation labelling rule

Pregnancy labelling of medications is a hotly debated issue in the field of teratology, and several studies have shown the limitations of providing pregnancy safety category ratings for medicines. In this recent academic highlights article, the authors summarise discussions which were held at an April 2017 meeting focussed on pregnancy pharmacogivilance and the FDAs pregnancy and lactation labelling rule. Further […]

» Read more

Additional data made available concerning first trimester dolutegravir use

Researchers from the ENTIS Paris COCHIN Center (Centre Régional de Pharmacovigilance et d’information sur le médicament) at the Assistance Publique-Hopitaux de Paris have published national surveillance data of first-trimester exposure to dolutegravir, raltegravir or elvitegravir in pregnancy, adding to the growing body of evidence available for integrase strand transfer inhibitors. More information can be found here.

» Read more

Developmental toxicity risks of medicines included on the WHO’s Essential Medicines List

A collaboration of researchers from the University of Washington School of Medicine and the Washington Center for Epidemiology and Environmental Health have published their findings of a review into the developmental toxicity risks for medicines included on the WHO’s Essential Medicines List. The authors described a large proportion of these medicines had limited data concerning developmental risks, identifying a clear need […]

» Read more
1 2 3 4 5 6